ES2104695T3 - Induccion de proteccion contra una infeccion virica. - Google Patents

Induccion de proteccion contra una infeccion virica.

Info

Publication number
ES2104695T3
ES2104695T3 ES91906386T ES91906386T ES2104695T3 ES 2104695 T3 ES2104695 T3 ES 2104695T3 ES 91906386 T ES91906386 T ES 91906386T ES 91906386 T ES91906386 T ES 91906386T ES 2104695 T3 ES2104695 T3 ES 2104695T3
Authority
ES
Spain
Prior art keywords
glycoprotein
induction
protection against
viral infection
htlv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91906386T
Other languages
English (en)
Inventor
Marc Girard
Marie-Paule Kieny
Claude Leclerc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Application granted granted Critical
Publication of ES2104695T3 publication Critical patent/ES2104695T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ESTA INVENCION SE REFIERE A UN METODO PARA POTENCIAR LA INMUNOGENECIDAD DE UNA GLICOPROTEINA ENVOLVENTE VIRICA EN UN ORGANISMO RECEPTOR. EL METODO COMPRENDE LA ADMINISTRACION AL RECEPTOR DE UNA COMPOSICION QUE COMPRENDE LA GLICOPROTEINA VIRICA ENVOLVENTE Y AL MENOS UN DERIVADO OLIGOPEPTIDO DE UNA SECUENCIA AMINOACIDA DE UNA GLICOPROTEINA ENVOLVENTE, DONDE EL OLIGOPEPTIDO CONTIENE O SE CORRESPONDE A EPITOPES VIRUS-NEUTRALIZANTES. EL METODO Y LA COMPOSICION SON UTILES PARA VACUNAS ANTI-VIRUS, TALES COMO HIV, SIV, HTLV-I, HTLV-II, O CUALQUIER RETROVIRUS CAPAZ DE INDUCIR SIDA EN SU RECEPTOR NATURAL.
ES91906386T 1990-03-19 1991-03-16 Induccion de proteccion contra una infeccion virica. Expired - Lifetime ES2104695T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49474990A 1990-03-19 1990-03-19

Publications (1)

Publication Number Publication Date
ES2104695T3 true ES2104695T3 (es) 1997-10-16

Family

ID=23965805

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91906386T Expired - Lifetime ES2104695T3 (es) 1990-03-19 1991-03-16 Induccion de proteccion contra una infeccion virica.

Country Status (10)

Country Link
EP (2) EP0472706B1 (es)
JP (2) JPH03271233A (es)
AT (1) ATE154244T1 (es)
AU (3) AU651816B2 (es)
CA (1) CA2057040A1 (es)
DE (1) DE69126486T2 (es)
DK (1) DK0472706T3 (es)
ES (1) ES2104695T3 (es)
GR (1) GR3024670T3 (es)
WO (1) WO1991014449A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976541A (en) * 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US5876724A (en) * 1990-03-19 1999-03-02 Institut Pasteur Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
US6139843A (en) * 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
DE69233271T2 (de) * 1991-04-02 2004-09-09 Albert Einstein College Of Medicine Of Yeshiva University Therapeutischer- und präventivimpfstoff gegen hiv
EP0613378A1 (en) * 1991-10-28 1994-09-07 Institut Pasteur Induction of protection against viral infection by synergy between viral proteins and viral peptides
FR2692898B1 (fr) * 1992-06-30 1995-06-02 Centre Nat Rech Scient Procédé d'obtention de protéines membranaires, et utilisation de ces protéines dans un but de diagnostic ou de vaccination.
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3688051T2 (de) * 1985-12-17 1993-06-24 Akzo Nv Immunochemisches reagenz.
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
EP0317804B1 (en) * 1987-11-24 1995-10-04 Abbott Laboratories HIV peptides and methods for detection of HIV
US5039522A (en) * 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
FR2650954B1 (fr) * 1989-08-18 1992-02-28 Pasteur Institut Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida

Also Published As

Publication number Publication date
ATE154244T1 (de) 1997-06-15
DE69126486T2 (de) 1998-01-15
DK0472706T3 (da) 1997-12-29
EP0742229A3 (en) 1998-06-03
CA2057040A1 (en) 1991-09-20
JPH03271233A (ja) 1991-12-03
AU651816B2 (en) 1994-08-04
GR3024670T3 (en) 1997-12-31
EP0472706B1 (en) 1997-06-11
JPH04506220A (ja) 1992-10-29
AU7196098A (en) 1998-08-13
DE69126486D1 (de) 1997-07-17
AU7498991A (en) 1991-10-21
EP0742229A2 (en) 1996-11-13
WO1991014449A1 (en) 1991-10-03
EP0472706A1 (en) 1992-03-04
AU6461594A (en) 1994-09-08

Similar Documents

Publication Publication Date Title
DK1409012T3 (da) Fremgangsmåder til fremkaldelse af et cytotoksisk immunrespons og derved anvendelige rekombinante abe-adenovirussammensætninger
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
DE68927348D1 (de) Künstlicher impfstoff gegen aids-virus
ATE306938T1 (de) Verwendung von cpg als adjuvans für hivimpstoff
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
NZ335612A (en) A composition containing cytotoxic specificT-cell epitopes being either Rev and/or Tat proteins from HIV virus for prevention and treatment of human immunodeficiency virus (HIV) infection
DK1034000T3 (da) Fremgangsmåde til fremstilling af vacciner til forebyggelse af de patogene virkninger relateret til en HIV-retrovirusinfektion
ATE429929T1 (de) Verbesserte impfstoffe
ES2104695T3 (es) Induccion de proteccion contra una infeccion virica.
NO20014841D0 (no) Anti-HIV-1 vaksine som omfatter hele eller del av HIV-1 TAT proteinet
AR032871A1 (es) Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana
ATE147782T1 (de) Primaten-lentivirus impfstoffe
ATE294857T1 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
WO1990013281A3 (en) Method of suppressing hiv infection
ES2058100T3 (es) Vacuna combinada.
WO2001008702A3 (en) Immunotherapy in hiv infected persons using vaccines after multi-drug treatment
OA09037A (en) Prevention and treatement of retroviral disease.
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
ES2095899T3 (es) Peptidos de la proteina gag de vih, su preparacion y uso.
ATE489966T1 (de) Verbundsuperimmunogen zur verwendung als bifunktioneller impfstoff (tat-gp160) zur behandlung von aids
IL139360A0 (en) Viral chimeras comprised of caev and hiv-1 genetic elements
ES2133408T3 (es) Nuevos aislados de virus vih-1 de un subtipo, y su diagnostico diferencial, vacuna contra la infeccion por vih-1 de este subtipo y procedimiento para preparar y usar el aislado de vih-1.
DK0545991T3 (da) Peptider, der blokerer infektioner med human immundefektvirus, og fremgangsmåder til anvendelse deraf
ES2141297T3 (es) Vacuna contra la babesiosis.
WO2004041997A3 (en) Immunotherapy regimens in hiv-infected patients

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 472706

Country of ref document: ES